Critical Challenges and Opportunities Even in non-pandemic times, rare and ultra-rare disease communities face staggering challenges as they work ceaselessly for awareness, support and treatment. It’s crucial to examine the impact of COVID-19 on rare diseases, which can help shed light on heightened hurdles as well...
Is it Time for Digital Health to Break Out of Isolation? The United States has been in an ongoing battle with substance addiction and opioid overdose, which has resulted in high rates of mortality; now with COVID-19, we are facing increased social isolation, more mental health...
In June 2020, the Health Resources and Services Administration (HRSA) reported that net purchasing volume under the 340B program in 2019 was at least $29.9 billion. This accounts for purchases made through wholesalers and excludes direct-from-manufacturer and some specialty distributor purchases – the total volume...
The opioid epidemic in the United States is a serious national crisis that affects public health as social and economic welfare. From 1999 to 2017, more than 700,000 people died from a drug overdose; of which, 218,000 were related to prescription opioid use/abuse.1 In 2017...
Patient adherence is critical to improving health outcomes and reducing costs to the health care system1. However, patient adherence remains a significant challenge, particularly in chronic diseases requiring frequent and ongoing pharmaceutical treatment. Health care professionals and health systems recognize this as a significant and...
From mobile devices to wearables and biosensors, digital innovation has led to an exponential increase in the availability of health-related data. While the healthcare market has traditionally been slow to adopt digital innovations (in 2017 14% of US clinician offices still relied on paper medical records) there are now a multitude of ways healthcare companies...
In May of 2018, the Trump administration released a proposal which it described as a blueprint to address rising pharmaceutical costs. The proposal, American Patients First, consisted of four key strategies for reform (you can read the full Jupiter assessment here) including an effort to...
In many respects, 2018 appeared as though Donald Trump might make good on his key campaign promise to curb increasing pharmaceutical prices. With public and legislative scrutiny of manufacturer pricing practices continually increasing, the Trump White House released their “blueprint” for addressing rising drug costs,...
As public and political scrutiny of drug prices continues, pharmaceutical companies are increasingly encountering new governmental efforts to control rising drug costs. At the federal level, this scrutiny resulted in the publication of the Trump administration’s American Patients First blueprint last year. While the major...
LONDON – Jan. 21, 2019 Jupiter Life Sciences Consulting, a global leader in market access and pricing strategy in the biopharmaceutical industry, are delighted to announce the appointment of Saleem J Shah (Sal) as Partner. Based in London, Sal will build and lead European...